Preclinical studies demonstrate that IGF1R inhibitors decrease tumour development, promote apoptosis, and interfere with critical pathways such as PI3K/AKT and MAPK/ERK, which are essential for tumour survival and proliferation [27,28,29]. This evidence concerns the gene MAPK1 and neoplasm.